Noah Greifer

Noah Greifer

Auto-generated profile, based on publicly available information

Noah Greifer

Institute for Quantitative Social Science, Harvard University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


6 January 2005
Verified
Dataset
Closed access
DHDaniel Ho
Daniel Ho
KIKosuke Imai
Kosuke Imai
GKGary King
Gary King
ESElizabeth Stuart
Elizabeth Stuart
NGNoah Greifer
Noah Greifer

1 June 2017 in Journal of the Society for Social Work and Research
Verified
Journal Article
Closed access
KKKirsten Kainz
Kirsten Kainz
NGNoah Greifer
Noah Greifer
AGAshley Givens
Ashley Givens
KSKaren Swietek
Karen Swietek
BLBrianna M. Lombardi
Brianna M. Lombardi
JKJamie L. Kohn
Jamie L. Kohn
Objective: This paper is a resource for applied researchers and journal reviewers who wish to learn more about propensity score methods, especially recent published recommendations for selecting and balancing covariates before conducting treatment effect analysis. Method: We reviewed and synthesized methodological studies of propensity score analysis from multiple disciplines in an effort to distill a cogent and defensible set of recommendations for research practice. Results: Selection of covariates for propensity score methods requires good understanding of empirical evidence and theory related to confounders of treatment assignment and the outcome, as well as clarity about the temporal relations among confounders, treatment, and outcome as measured in the data set in use. Some variables are not appropriate for inclusion in a propensity score model, and some data sets do not include sufficient variables for propensity score analysis. Achieving balance in the model covariates after conditioning on the propensity score should be an iterative process where models are respecified until proper balance is obtained. Important steps for propensity score methods include reporting results from iterative modeling and balance checks, and then defending the final sample conditioned on the propensity score before analysis of treatment effects. These steps are often overlooked in published research. Conclusion: Propensity score methods can be useful tools for reducing bias due to observed confounders. To credibly reduce bias, however, researchers must execute recommended practice for selecting and balancing covariates.

17 May 2023 in Methods in Ecology and Evolution
Verified
Journal Article
Open access
TSTiago R. Simões
Tiago R. Simões
NGNoah Greifer
Noah Greifer
JBJoëlle Barido‐Sottani
Joëlle Barido‐Sottani
SPStephanie E. Pierce
Stephanie E. Pierce
Relaxed clock Bayesian evolutionary inference (BEI) enables the co‐estimation of phylogenetic trees and evolutionary parameters associated with models of character and lineage evolution. Fast advances in new model developments over the past decade have boosted BEI as a major macroevolutionary analytical framework using morphological and/or molecular data across vastly different study systems. However, there is limited availability of bioinformatic tools to pre‐ and postprocess data from BEI, such as identifying morphological data partitions, or statistically testing and creating publication quality plots of evolutionary hypotheses. Here, we introduce EvoPhylo, an r package to perform automated morphological character partitioning and analyse macroevolutionary parameter from relaxed clock (time‐calibrated) BEI outputted by the programs Mr.Bayes and BEAST2. These include rates of evolution and mode of selection for each character partition, diversification rate parameters, and handling fossil‐only posterior trees. We present the theoretical background behind EvoPhylo's functions and analytical tools for evolutionary hypothesis testing, its potential uses, and interpretation of its results with a series of vignettes and links to a step‐by‐step tutorial using examples from two empirical datasets. EvoPhylo will facilitate the use of Bayesian relaxed clocks as a tool for macroevolutionary inference across a wide range of users and fields of research, especially those that make usage of morphological datasets, from paleontological to total evidence dating analyses.

9 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MYMichael Yan
Michael Yan
SSSamantha Sigurdson
Samantha Sigurdson
NGNoah Greifer
Noah Greifer
TKThomas A. C. Kennedy
Thomas A. C. Kennedy
TTTzen Szen Toh
Tzen Szen Toh
BLBenjamin H Lok
Benjamin H Lok
Despite evidence for the superiority of twice-daily (BID) radiotherapy schedules, their utilization in practice remains logistically challenging. Hypofractionation (HFRT) is a commonly implemented alternative. We aim to compare the outcomes and toxicities in limited-stage small-cell lung cancer (LS-SCLC) patients treated with hypofractionated versus BID schedules. A bi-institutional retrospective cohort review was conducted of LS-SCLC patients treated with BID (45 Gy/30 fractions) or HFRT (40 Gy/15 fractions) schedules from 2007 to 2019. Overlap weighting using propensity scores was performed to balance observed covariates between the two radiotherapy schedule groups. Effect estimates of radiotherapy schedule on overall survival (OS), locoregional recurrence (LRR) risk, thoracic response, any ≥grade 3 (including lung, and esophageal) toxicity were determined using multivariable regression modelling. A total of 173 patients were included in the overlap-weighted analysis, with 110 patients having received BID treatment, and 63 treated by HFRT. The median follow-up was 20.4 months. Multivariable regression modelling did not reveal any significant differences in OS (hazard ratio [HR] 1.67, p = 0.38), LRR risk (HR 1.48, p = 0.38), thoracic response (odds ratio [OR] 0.23, p = 0.21), any ≥grade 3+ toxicity (OR 1.67, p = 0.33), ≥grade 3 pneumonitis (OR 1.14, p = 0.84), or ≥grade 3 esophagitis (OR 1.41, p = 0.62). HFRT, in comparison to BID radiotherapy schedules, does not appear to result in significantly different survival, locoregional control, or toxicity outcomes.